X

Trial Profile

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 813160 (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Paclitaxel
Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

29 Aug 2023 This study has been completed in Belgium (End date: 2023-06-14), according to European Clinical Trials Database record.
30 Jun 2023 Status changed from active, no longer recruiting to completed.
26 Jun 2023 This study has been completed in Germany (End date: 2023-06-14), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com